Exosens Shares Hit Record High at €68.80, Up 109% in One Year
Exosens reached an unprecedented peak this Tuesday, March 10, with its share price hitting €68.80 during the session, surpassing the previous high of March 2. At midday, the share is trading at €68.30, up 3.64% from the previous day's close. This increase is part of a strong upward trend, with a performance of nearly 40% over three months and a doubling of the share price over one year.
Exosens Surpasses Previous Record High in Morning Trading
The Exosens share surpassed its previous record high of €68.80, set on March 2, in morning trading, confirming the buying momentum observed since the beginning of the year. The optoelectronic technology specialist has advanced 4.59% over seven days and displays an impressive 109.1% over twelve months. This surge occurs in a context of a generalized rebound in European markets. The CAC 40 is up 2.31% in session, while the DAX gains 2.22% and the FTSE 100 is up 1.67%. In Asia, the Nikkei 225 ended the day up 2.88%. However, the VIX, measured on March 6, remained at a high level of 29.49 points, indicating that operators remain cautious despite the renewed appetite for risk observed this Tuesday.
Significant Meaning in Today's Trading Session
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Graphically, today's session holds particular significance. By surpassing €68.30, the share price is now well above the upper Bollinger band, set at €67.45, indicating a pronounced bullish extension and a significant departure from the usual price zone. The 50-day moving average, located at €56.33, is now more than 21% below the current price, confirming the strength of the upward trend. The former resistance at €65.90 – which was the previous day's closing price – could now act as support in case of a pullback. The next key date for the company is scheduled for April 27, when Exosens will publish its first-quarter 2026 results. The general meeting is scheduled for May 22.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
